Wednesday, September 12, 2018 1:29:38 PM
Sometimes it is not what is said that is important but rather what is not said..
Today's press release:
This acceptance as a presentation of late-breaking clinical trial results is based on the ability of REDUCE-IT to address a critical question in cardiovascular prevention. The AHA has reviewed the design of the REDUCE-IT study, however, they have not yet seen the results of the study. As Amarin has guided in the past, topline results of this study are anticipated to be made public prior to the end of this month, September 2018. The AHA has not been provided any advanced access to the results of this study.
Notice they stated that the AHA has NOT yet seen the results of the study. Notice that it did not state that Amarin hasn't seen it like JT has said in the past. To push to present at the AHA w/ knowledge of the result is a positive as they would not be in a hurry if it was negative. Also, you can not provide advanced access to the results if you don't have it. You'd simply say we still do not have the results.
Essentially we know they have the results. The question is whether they completely understand it and that is the sole reason why it has not been PR'ed yet. I could be reading into something that isn't there or wasn't intentional but the way its written subtly implies they have it and by PR'ing their push to present it asap, reflects what is likely a positive outcome.
Today's press release:
This acceptance as a presentation of late-breaking clinical trial results is based on the ability of REDUCE-IT to address a critical question in cardiovascular prevention. The AHA has reviewed the design of the REDUCE-IT study, however, they have not yet seen the results of the study. As Amarin has guided in the past, topline results of this study are anticipated to be made public prior to the end of this month, September 2018. The AHA has not been provided any advanced access to the results of this study.
Notice they stated that the AHA has NOT yet seen the results of the study. Notice that it did not state that Amarin hasn't seen it like JT has said in the past. To push to present at the AHA w/ knowledge of the result is a positive as they would not be in a hurry if it was negative. Also, you can not provide advanced access to the results if you don't have it. You'd simply say we still do not have the results.
Essentially we know they have the results. The question is whether they completely understand it and that is the sole reason why it has not been PR'ed yet. I could be reading into something that isn't there or wasn't intentional but the way its written subtly implies they have it and by PR'ing their push to present it asap, reflects what is likely a positive outcome.
Recent A News
- Agilent Launches New GC Systems with GC Assist to Improve Laboratory Efficiency and Data Quality • Business Wire • 05/26/2026 12:00:00 PM
- Agilent Launches Multi-Attribute Method (MAM) Solution for BioPharma Quality Control • Business Wire • 05/26/2026 12:00:00 PM
- Agilent Unveils the 9500 ICP-MS: Redefining Trace Element Analysis • Business Wire • 05/22/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2026 08:06:22 PM
- Agilent Launches 1290 Infinity III Fluorescence Detector for Confident Trace Analysis at UHPLC Speed • Business Wire • 05/21/2026 12:00:00 PM
- Agilent Announces Cash Dividend of 25.5 Cents per Share • Business Wire • 05/20/2026 08:27:00 PM
- Agilent to Supply Next Generation Alarm Resolution Technology to U.S. Airport Security Screening Checkpoints ahead of FIFA World Cup 2026 • Business Wire • 05/19/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/12/2026 08:11:55 PM
- Agilent to Participate in Jefferies Global Healthcare Conference • Business Wire • 05/11/2026 08:15:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 08:18:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 12:05:15 PM
- Agilent Names Michael Buckner as Chief Legal Officer • Business Wire • 05/04/2026 12:00:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/29/2026 08:42:15 PM
- Agilent to Announce Second-Quarter Fiscal Year 2026 Financial Results on May 27 • Business Wire • 04/28/2026 08:15:00 PM
- Agilent Showcases Cancer Research Solutions at AACR 2026 • Business Wire • 04/15/2026 12:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 04/04/2026 01:30:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:05:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:06:44 PM
- Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader • Business Wire • 04/01/2026 12:00:00 PM
- Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma • Business Wire • 03/26/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 08:39:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 08:36:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 08:29:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 08:27:06 PM
